B+
Bull case
30%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
PGEN
PrecigenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$4.40
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+25.1
Score
AI commentary
News flow is sparse and mostly company-result driven. The March 25, 2026 update materially strengthened the fundamental story versus a pure filing-monitoring setup, but low coverage, limited analyst-revision visibility, and a negative deterministic prior argue for a monitoring-style stance rather than an aggressive bullish call. Headline buzz appears low, and no reliable social dataset was provided to raise confidence.
RankAlpha Sentiment Codex - 2026-05-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystFirst post-launch 10-Q should test whether PAPZIMEOS demand is converting into repeat revenueHigh impact
Management said PAPZIMEOS generated $3.4 million of Q4 2025 net product revenue, demand increased in Q1 2026, patient hub enrollment surpassed 300, payer coverage reached about 90% of insured US lives, and a permanent J-code became effective April 1, 2026; the next quarterly filing is the nearest hard checkpoint for whether that early launch momentum is holding [#PR-2026-03-25] [#8-K-2026-03-25].
2026-12-31eventEuropean PAPZIMEOS review and redosing study are the main non-US forward hooksHigh impact
The March 25, 2026 company release said the PAPZIMEOS Marketing Authorization Application had been validated by the EMA and remained under review, and that an open-label redosing study had been initiated in adults with RRP. Both matter for duration-of-benefit and geographic expansion, but timing and outcome visibility are still limited [#PR-2026-03-25].
2026-12-31catalystUS PAPZIMEOS commercialization ramp versus cash-flow break-even claimHigh impact
Precigen said 2025 marked its transition to a commercial-stage company after August 2025 FDA approval of PAPZIMEOS, and the March 25, 2026 press release said cash, cash equivalents, and investments of $100.4 million were expected to fund operations to cash-flow break-even. If PAPZIMEOS adoption and collections scale, that could support re-rating; if uptake lags, financing risk returns quickly [#10-K-2026-03-25] [#PR-2026-03-25].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology